Floatz logo

121 assets in Urinary Bladder Carcinoma

Therapeutic assets addressing Urinary Bladder Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cis-Diamminedichloroplatinum Ii
Urinary Bladder Carcinoma
G1 Therapeutics, Inc.P3BBB (72)
Trastuzumab
Urinary Bladder Carcinoma
NKGen Biotech, Inc.P2BB (70)
Carboplatin
Urinary Bladder Carcinoma
G1 Therapeutics, Inc.P3BB (67)
Cyclophosphamide
Urinary Bladder Carcinoma
Beijing BiotechP3BB (66)
Pembrolizumab
Urinary Bladder Carcinoma
Essen BiotechP3BB (66)
Adriamycin
Urinary Bladder Carcinoma
Toray Industries, IncP3BB (65)
Nivolumab
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2/3BB (64)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Urinary Bladder Carcinoma
Merck Sharp & Dohme LLCP3B (62)
Fluorouracilum
Urinary Bladder Carcinoma
Arcus Biosciences, Inc.P2B (62)
Irinotecan
Urinary Bladder Carcinoma
Toray Industries, IncP3B (62)
Relatlimab
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2/3B (62)
Atezolizumab
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2B (61)
Oxaliplatin
Urinary Bladder Carcinoma
Arcus Biosciences, Inc.P2B (60)
Fludeoxyglucose
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (55)
Palbociclib
Urinary Bladder Carcinoma
Brown UniversityP2CCC (55)
Ipilimumab
Urinary Bladder Carcinoma
M.D. Anderson Cancer CenterP2CCC (54)
Pertuzumab
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (54)
Trastuzumab Emtansine
Urinary Bladder Carcinoma
Hoffmann-La RocheP2CCC (54)
Vismodegib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (54)
Binimetinib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Capivasertib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Crizotinib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Dabrafenib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Dasatinib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Defactinib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Fexagratinib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Gsk-2636771
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipatasertib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Larotrectinib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Osimertinib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Sapanisertib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Tocilizumab
Urinary Bladder Carcinoma
M.D. Anderson Cancer CenterP2CCC (53)
Trametinib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (53)
[18f]f-resca-rt4
Urinary Bladder Carcinoma
RenJi HospitalP2/3CCC (52)
[18F]F-RESCA-T4
Urinary Bladder Carcinoma
RenJi HospitalP2/3CCC (52)
[68ga]ga-nota-rt4
Urinary Bladder Carcinoma
RenJi HospitalP2/3CCC (52)
[68ga]ga-nota-t4
Urinary Bladder Carcinoma
RenJi HospitalP2/3CCC (52)
Adavosertib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (52)
Recombinant Ephb4-Hsa Fusion Protein
Urinary Bladder Carcinoma
University of Southern CaliforniaP2CCC (52)
Brigimadlin
Urinary Bladder Carcinoma
Boehringer IngelheimP2CCC (51)
Dpx-Survivac
Urinary Bladder Carcinoma
ImmunoVaccine Technologies, Inc. (IMV Inc.)P2CCC (51)
Durvalumab
Urinary Bladder Carcinoma
M.D. Anderson Cancer CenterP1/2CCC (51)
Enzalutamide
Urinary Bladder Carcinoma
Cancer Research UKP1/2CCC (51)
FAPI74
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (51)
her3-dxd
Urinary Bladder Carcinoma
Daiichi SankyoP2CCC (51)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Urinary Bladder Carcinoma
OncoNano Medicine, Inc.P1/2CCC (51)
Resiquimod
Urinary Bladder Carcinoma
Institut BergoniéP2CCC (51)
Taselisib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Ulixertinib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Showing 1 to 50 of 121 assets
PreviousPage 1 of 3Next